Eupraxia Pharmaceuticals, Inc. EPRX 深 滬
等待開盤 03-26 09:30:00 美东时间
7.08
+0.190
+2.76%
華盛通- 最 高7.505
- 今 開7.05
- 成交量 15.41万股
- 最 低 7.04
- 昨 收 6.89
- 總市值 4.35亿
- 52周最高 9.32
- 市盈率 靜 --
- 換手率 0.25%
- 52周最低 2.6801
- 委 比 35.66%
- 總股本 6150.32万
- 歷史最高 9.32
- 量 比 0.57
- 振 幅 6.75%
- 歷史最低 2.20
- 每 手 1
- 風險率 1.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eupraxia Pharmaceuticals Boasts $900 Million Peak Sales Potential: Analyst
William Blair starts Eupraxia at Outperform as the analyst flags unmet need and sizable market potential.
03-24 01:59
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Semtech To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts changed outlook on top names: Morgan Stanley raised Lemonade's PT to $85, Mizuho cut Canadian Solar's PT to $19, Piper Sandler raised Tandem Diabetes' PT to $33, Stifel increased Ichor's PT to $55, Needham raised Semtech's PT to $105, HC Wainwright cut Eupraxia Pharma's PT to $11, Evercore ISI Group raised National Storage Affiliates Trust's PT to $41.
03-17 19:49
HC Wainwright & Co. Maintains Buy on Eupraxia Pharmaceuticals, Lowers Price Target to $11
HC Wainwright & Co. analyst Brandon Folkes maintains Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Buy and lowers the price target from $12 to $11.
03-17 18:57
Eupraxia Pharmaceuticals Q4 EPS $(0.37) Misses $(0.16) Estimate
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.16) by 131.25 percent. This is a 68.18 percent decrease over losses of $(0.22) per
03-13 14:59
Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
Eupraxia Pharmaceuticals reported a net loss of $16.7 million for Q4 2025, up from $7.5 million in 2024, due to increased R&D and administrative costs. Cash reserves rose to $80.5 million as of December 2025, up from $33.1 million a year earlier, supported by a public offering that raised $63.2 million. The company achieved significant clinical milestones in its EP-104GI program, with positive 52-week follow-up and biopsy data from the RESOLVE tr...
03-13 01:03
Eupraxia Pharmaceuticals shares are trading lower after the company announced a proposed public offering.
Eupraxia Pharmaceuticals shares are trading lower after the company announced a...
02-19 05:34
Eupraxia Pharmaceuticals Commences Common Stock Offering; Terms Not Disclosed
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local,
02-19 05:29
Eupraxia Pharmaceuticals Announces Proposed Public Offering
Eupraxia Pharmaceuticals Inc. filed a preliminary prospectus supplement for a proposed public offering of common shares or pre-funded warrants. The offering is subject to market conditions and customary closing conditions, including TSX and Nasdaq listing. Cantor, LifeSci Capital, and Bloom Burton are acting as joint book-running managers and co-manager. Proceeds will primarily fund the advancement of EP-104GI for Eosinophilic Esophagitis, includ...
02-18 21:01
美股大行评级 | 阿斯麦、美光科技、SanDisk获大行上调目标价；美国银行、富国银行绩后遭多家机构下调目标价
今日重点评级关注：Benchmark：维持TNL Mediagene"投机性买入"评级，目标价从3.5美元升至14美元；康托·菲茨杰拉德：维持Eupraxia Pharmaceuticals"超配"评级，目标价从11美元升至19美元
01-16 10:04
